Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2017 Mar 12

PMID 28283926

Citations 13

Authors

Maria Marketou

Yashaswi Gupta

Shashank Jain

Panos Vardas

Affiliations

Soon will be listed here.

Abstract

Blood pressure management in hypertensive patients with metabolic abnormalities is challenging, since many of the antihypertensive drugs adversely affect metabolism. Besides effective control of blood pressure in patients with hypertension, third-generation beta-blockers such as nebivolol offer additional benefits for central hemodynamics and neutral or beneficial effects on metabolism. Emerging clinical data suggest that nebivolol also has similar effects on metabolism in obese hypertensive and hypertensive diabetic patients. The present article will provide a systematic analysis of the pathophysiological links among hypertension, insulin resistance, and metabolic syndrome. We will also summarize the available clinical evidence regarding the metabolic effects of beta-blockers in hypertensive patients, with an emphasis on nebivolol. Nebivolol exerts neutral or beneficial effects on insulin sensitivity and lipid metabolism in hypertensive patients, owing to its nitric oxide-mediated vasodilatory and antioxidative properties. Thus, nebivolol could be a favorable therapeutic option for the treatment of hypertension in patients with impaired glucose and lipid metabolism.

Citing Articles

Angiotensin-(1-7) and Central Control of Cardiometabolic Outcomes: Implications for Obesity Hypertension.

Vernail V, Lucas L, Miller A, Arnold A Int J Mol Sci. 2025; 25(24.

PMID: 39769086 PMC: 11677932. DOI: 10.3390/ijms252413320.

Second-Generation Antipsychotics Induce Metabolic Disruption in Adipose Tissue-Derived Mesenchymal Stem Cells Through an aPKC-Dependent Pathway.

Varalda M, Venetucci J, Nikaj H, Kankara C, Garro G, Keivan N Cells. 2025; 13(24.

PMID: 39768174 PMC: 11674800. DOI: 10.3390/cells13242084.

β-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress.

Drygala S, Radzikowski M, Maciejczyk M Front Pharmacol. 2025; 15:1489657.

PMID: 39759452 PMC: 11695285. DOI: 10.3389/fphar.2024.1489657.

Predicting the toxic side effects of drug interactions using chemical structures and protein sequences.

Zhang L, Sheng Y, Yang J, Hu Z, Peng B Sci Rep. 2024; 14(1):31503.

PMID: 39733005 PMC: 11682051. DOI: 10.1038/s41598-024-82981-9.

Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.

Przezak A, Bielka W, Pawlik A Int J Mol Sci. 2022; 23(12).

PMID: 35742943 PMC: 9224227. DOI: 10.3390/ijms23126500.

References

Ozyildiz A, Eroglu S, Bal U, Atar I, Okyay K, Muderrisoglu H . Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension. J Cardiovasc Pharmacol Ther. 2016; 22(1):65-70. DOI: 10.1177/1074248416644987. View

Mule G, Cerasola G . The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens (Greenwich). 2006; 8(3):195-201. PMC: 8109384. DOI: 10.1111/j.1524-6175.2006.04716.x. View

Huang P . eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009; 20(6):295-302. PMC: 2731551. DOI: 10.1016/j.tem.2009.03.005. View

Cheung B, Li C . Diabetes and hypertension: is there a common metabolic pathway?. Curr Atheroscler Rep. 2012; 14(2):160-6. PMC: 3314178. DOI: 10.1007/s11883-012-0227-2. View

Marazzi G, Volterrani M, Caminiti G, Iaia L, Cacciotti L, Massaro R . Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv Ther. 2010; 27(9):655-64. DOI: 10.1007/s12325-010-0053-2. View

Messerli F, Bell D, Fonseca V, Katholi R, McGill J, Phillips R . Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007; 120(7):610-5. DOI: 10.1016/j.amjmed.2006.10.017. View

Sironi A, Gastaldelli A, Mari A, Ciociaro D, Positano V, Postano V . Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension. 2004; 44(2):127-33. DOI: 10.1161/01.HYP.0000137982.10191.0a. View

Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, NICOD P . Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994; 89(6):2634-40. DOI: 10.1161/01.cir.89.6.2634. View

Mule G, Calcaterra I, Nardi E, Cerasola G, Cottone S . Metabolic syndrome in hypertensive patients: An unholy alliance. World J Cardiol. 2014; 6(9):890-907. PMC: 4176799. DOI: 10.4330/wjc.v6.i9.890. View

10.

Munzel T, Gori T . Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009; 54(16):1491-9. DOI: 10.1016/j.jacc.2009.05.066. View

11.

Zhou M, Schulman I, Raij L . Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens. 2009; 28(3):527-35. DOI: 10.1097/HJH.0b013e3283340da8. View

12.

Malacco E . Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients. Eur Rev Med Pharmacol Sci. 2010; 14(5):427-34. View

13.

Veverka A, Salinas J . Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag. 2007; 3(5):647-54. PMC: 2291309. View

14.

Owada A, Suda S, Hata T, Miyake S . The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens. 2001; 23(4):305-16. DOI: 10.1081/ceh-100102669. View

15.

Salvetti A, Brogi G, Di Legge V, Bernini G . The inter-relationship between insulin resistance and hypertension. Drugs. 1993; 46 Suppl 2:149-59. DOI: 10.2165/00003495-199300462-00024. View

16.

Vinker S, Alkalay A, Hoffman R, Elhayany A, Kaiserman I, Kitai E . Long-term adherence to antihypertensive therapy: a survey in four primary care clinics. Expert Opin Pharmacother. 2008; 9(8):1271-7. DOI: 10.1517/14656566.9.8.1271. View

17.

Manrique C, Whaley-Connell A, Sowers J . Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009; 11(6):309-15. PMC: 8673057. DOI: 10.1111/j.1751-7176.2009.00119.x. View

18.

Navare H, Frye R, Cooper-DeHoff R, Shuster J, Hall K, Schmidt S . Atenolol exposure and risk for development of adverse metabolic effects: a pilot study. Pharmacotherapy. 2010; 30(9):872-8. PMC: 2999810. DOI: 10.1592/phco.30.9.872. View

19.

Sarafidis P, Bakris G . Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006; 99(7):431-6. DOI: 10.1093/qjmed/hcl059. View

20.

Peter P, Martin U, Sharma A, Dunne F . Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther. 2006; 31(2):153-9. DOI: 10.1111/j.1365-2710.2006.00718.x. View